# Risk of pseudotumor cerebri added to labeling for gonadotropin-releasing hormone agonists #### (2022) - Food and Drug Administration **Link**:: https://www.fda.gov/media/159663/download **DOI**:: **Links**:: **Tags**:: #paper **Cite Key**:: [@Food_and_Drug_Administration2022-be] ### Abstract ``` ``` ### Notes